Literature DB >> 795579

In vitro effect of thymosin on T-lymphocyte rosette formation in rheumatic diseases.

H Moutsopoulos, K H Fye, S Sawada, M J Becker, A Goldstein, N Talal.   

Abstract

The in vitro effect of calf thymosin fraction 5 on T-rosette forming cells (E-RFC) was studied in Sjögren's syndrome (SS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). The baseline percent E-RFC in sixteen normal controls was67-2 +/- 6-9. E-RFC was significantly decreased in SLE (42-6 +/- 17-0, P less than 0-0001) and SS (51-8 +/- 16-9, P less than 0-002) but not in RA (59-7 +/- 14-1). Ten of twenty-five SS patients and two of eleven RA patients had less than 50% E-RFC, and all showed a significant increase after incubation with thymosin (+ 16-5 +/- 6-5%, P less than 0-0001, and + 11 +/- 4-9%, P less than 0-001, respectively). Eleven of sixteen SLE patients had less than 50% E-RFC. Their response to thymosin was less dramatic but still statistically significant (+ 5-3 +/- 6-0%, P = 0-03). There was no response to thymosin in control subjects or in patients with baseline E-RFC greater than 50%. No increase in E-RFC was seen after incubation with calf spleen fraction 5 or known stimulators of cyclic-AMP. Sera from four active SLE patients, as well as the supernatant obtained from overnight culture of the lymphocytes from one SLE patients, were able to block T-rosette formation by normal lymphocytes, even after exposure to thymosin. Two 'blocking' sera were fractionated by sucrose density gradient ultracentrifucation. In one, the blocking capacity was found to reside in the 19S region containing IgM. In the second, the blocking capacity was in the 7S region containing IgG. Four 'blocking' lupus sera were depleted of IgG or IgM by immunoabsorption with goat anti-human IgG or goat anti-human IgM sepharose 4B. The blocking ability in three sera was partially decreased by depletion of either IgG or IgM, and in a fourth, only by removing IgG. The percent of lymphocytes staining with fluorescein labelled goat anti-human immunoglobulin antisera was increased in SLE patients (35-9 +/- 20-2 vs 21-7 +/- 5-9 in controls, P = 0-02). After overnight culture, the percent of staining cells decreased to normal values. These results suggest that thymosin can stimulate the differentiation of T-lymphocytes in patients with SS, SLE, and RA when the baseline E-RFC is decreased. Furthermore, the decreased percent E-RFC in SLE is probably due to cell-bound anti-lymphocyte antibodies that block sheep erythrocyte receptors on the T-cell and, possibly, thymosin receptors on undifferentiated lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 795579      PMCID: PMC1540966     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The oral component of Sjögren's syndrome.

Authors:  T E Daniels; S Silverman; J P Michalski; J S Greenspan; R A Sylvester; N Talal
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1975-06

2.  Effect of thymosin on thymocyte proliferation and autoimmunity in NZB mice.

Authors:  N Talal; M Dauphinee; R Pillarisetty; R Goldblum
Journal:  Ann N Y Acad Sci       Date:  1975-02-28       Impact factor: 5.691

3.  In-vitro demonstration of thymic hormone in the mouse by conversion of precursor cells into lymphocytes.

Authors:  K Komuro; E A Boyse
Journal:  Lancet       Date:  1973-04-07       Impact factor: 79.321

4.  Vulnerability of cell-surface receptors to autoimmune reactions.

Authors:  P R Carnegie; I R Mackay
Journal:  Lancet       Date:  1975-10-11       Impact factor: 79.321

5.  Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance.

Authors:  J S Flier; C R Kahn; J Roth; R S Bar
Journal:  Science       Date:  1975-10-03       Impact factor: 47.728

6.  Antibodies binding polyriboadenylic acid in systemic lupus erythematosus. Immunochemical characterization and isolation by affinity chromatography.

Authors:  R J Pillarisetty; M J Becker; D W Palmer; N Talal
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

7.  Analyses of lymphocytes from patients with rheumatoid arthritis and systemic lupus erythematosus. Occurrence of interfering cold-reactive antilymphocyte antibodies.

Authors:  R J Winchester; J B Winfield; F Siegal; P Wernet; Z Bentwich; H G Kunkel
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

8.  The human rosette-forming cell as a marker of a population of thymus-derived cells.

Authors:  J Wybran; M C Carr; H H Fudenberg
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

9.  Thymosin activity in patients with cellular immunodeficiency.

Authors:  D W Wara; A L Goldstein; N E Doyle; A J Ammann
Journal:  N Engl J Med       Date:  1975-01-09       Impact factor: 91.245

10.  Thymosin-induced reduction of "null cells" in peripheral-blood lymphocytes of patients with systemic lupus erythematosus.

Authors:  M A Scheinberg; E S Cathcart; A L Goldstein
Journal:  Lancet       Date:  1975-02-22       Impact factor: 79.321

View more
  2 in total

1.  Influence of thymosin on E-rosette formation of lymphoid cells in leukemic and nonleukemic children.

Authors:  H Winterleitner; W Rella; G Stingl; W Knapp
Journal:  Blut       Date:  1979-04-20

2.  Immunoregulation in Sjögren's syndrome: influence of serum factors on T-cell subpopulations.

Authors:  H M Moutsopoulos; A S Fauci
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.